Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for Coya Therapeutics in a report released on Monday, May 19th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of ($0.50) for the quarter. The consensus estimate for Coya Therapeutics' current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics' Q2 2026 earnings at ($0.46) EPS, Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.49) EPS and FY2026 earnings at ($1.93) EPS.
Coya Therapeutics (NASDAQ:COYA - Get Free Report) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.44) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.44). The company had revenue of $257.88 million for the quarter, compared to analysts' expectations of $2.63 million.
COYA has been the topic of several other research reports. Chardan Capital reissued a "buy" rating and set a $14.00 target price on shares of Coya Therapeutics in a research note on Tuesday, May 13th. D. Boral Capital reissued a "buy" rating and set a $18.00 target price on shares of Coya Therapeutics in a research note on Tuesday, April 22nd.
Read Our Latest Report on Coya Therapeutics
Coya Therapeutics Stock Up 0.7%
COYA stock opened at $5.97 on Tuesday. Coya Therapeutics has a twelve month low of $4.65 and a twelve month high of $10.24. The stock has a market cap of $99.85 million, a P/E ratio of -9.18 and a beta of 0.49. The business's 50-day moving average price is $6.03 and its 200-day moving average price is $6.16.
Institutional Trading of Coya Therapeutics
A number of large investors have recently added to or reduced their stakes in the company. DME Capital Management LP increased its stake in Coya Therapeutics by 29.2% in the 4th quarter. DME Capital Management LP now owns 1,646,440 shares of the company's stock worth $9,434,000 after acquiring an additional 372,414 shares during the last quarter. AIGH Capital Management LLC increased its stake in Coya Therapeutics by 85.0% in the 4th quarter. AIGH Capital Management LLC now owns 1,201,152 shares of the company's stock worth $6,883,000 after acquiring an additional 551,725 shares during the last quarter. CM Management LLC increased its stake in Coya Therapeutics by 25.0% in the 1st quarter. CM Management LLC now owns 200,000 shares of the company's stock worth $1,294,000 after acquiring an additional 40,000 shares during the last quarter. Dauntless Investment Group LLC bought a new stake in Coya Therapeutics in the 1st quarter worth approximately $1,083,000. Finally, Geode Capital Management LLC increased its stake in Coya Therapeutics by 5.8% in the 4th quarter. Geode Capital Management LLC now owns 150,576 shares of the company's stock worth $863,000 after acquiring an additional 8,267 shares during the last quarter. Institutional investors own 39.75% of the company's stock.
Coya Therapeutics Company Profile
(
Get Free Report)
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Coya Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Coya Therapeutics wasn't on the list.
While Coya Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
